Judith P.
- Country
- The Netherlands
- Department
- Klinische Immunologie
Research Overview
- Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
- Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease
Data & Insights
Has run more than one trial at 3 of 64 partner sites.
Specializations
Respiratory Medicine
The investigator specializes in treating interstitial lung diseases (ILD), particularly those associated with connective tissue diseases (CTD). Their research explores innovative therapeutic approaches for managing complex respiratory conditions.
- Interstitial Lung Disease Management
- Connective Tissue Disease Complications
- Advanced Respiratory Care
Their work focuses on evaluating new treatment options to prevent lung volume decline in affected patients.
Immunology
The investigator demonstrates expertise in treating primary immunodeficiency diseases (PIDD), with particular attention to developing and evaluating novel therapeutic approaches for immune disorders.
- Primary Immunodeficiency Treatment
- Subcutaneous Immunoglobulin Therapy
- Immunological Disorders
Their research encompasses pharmacokinetic evaluation of innovative immunological treatments for patients with compromised immune systems.
Therapeutic Innovation
The investigator's work extends to evaluating novel therapeutic agents, including belimumab and advanced immunoglobulin formulations for treating complex medical conditions.
- Novel Drug Development
- Treatment Optimization
- Clinical Applications
Their research aims to enhance treatment outcomes through innovative therapeutic approaches and drug delivery systems.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.